empty
 
 
de
Suche
Support
Sofortige Kontoeröffnung
Handelsplattform
Einzahlen / Auszahlen
Suche
Für Anfänger Für Trader Für Partner Machen Sie eine Pause Über uns
de
#ACB Zurück zur Liste #AMGN

Währungsrechner

Alnylam Pharmaceuticals Inc.
255.14 USD
09 Sep 2026 21:59
Preisveränderung (% chg)
$-0.02
(-0.01%)
Schließung
Schließung

Schließungspreis, der vorherige Tag.
$261.39
Eröffnung
Eröffnung

Eröffnungspreis.
$262.98
Höchstpreis
Höchstpreis

Höchstpreis für den letzten Tag des Handels.
$261.39
Mindestpreis
Mindestpreis

Mindestpreis
$252.66
52 Wochen. max.
52 Wochen. max.

Höchstpreis für die letzten 52 Wochen.
$261.39
52 Wochen. min.
52 Wochen. min.

Mindestpreis für die letzten 52 Wochen.
$237.09
Archiv herunterladen
Buy
256.64
Sell
255.14
Open the chart in full screen view
Buy
256.64
Sell
255.14
Archiv herunterladen
Open the chart in full screen view

Alnylam Pharmaceuticals Inc. About company

Alnylam Pharmaceuticals Inc. is an American biopharmaceutical company, founded in 2002. The firm is mainly involved in the research and development of drugs for treating genetic disorders.

In 2016, Alnylam Pharmaceuticals Inc. was added to the Forbes list of the world’s 100 most innovative growth companies.

This year, the market capitalization of Alnylam Pharmaceuticals Inc. totals $17.65 billion. In 2021, it raised revenue of $844.29 million. In the first six months of 2022, the company earned as much as $224.82 million.

Alnylam Pharmaceuticals Inc.’s shares and factors shaping their value

The company has been listed on the NASDAQ exchange since 2004 under the ALNY ticker. Its share value currently totals $200-205. Over the past 12 months, ALNY has fluctuated in the range of $117 to $236.

When trading the firm’s stock, you should pay attention to the following factors:

  • The company has a heavy dependence on the state of the healthcare sector as a whole. Thus, new COVID outbreaks have a negative influence on its revenue growth;
  • The company occasionally introduces new drugs to the market, conducting clinical and laboratory trials and publishing the results beforehand;
  • Constantly growing revenues are the firm’s advantage;
  • Enough own funds to finance projects without the need to additionally issue securities.

Können Sie momentan nicht telefonieren?
Dann stellen Sie Ihre Frage im Chat.